NASDAQ:HTGM - HTG Molecular Diagnostics Stock Price, Price Target & More

HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) posted its quarterly earnings results on Thursday, May, 10th. The medical research company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.04. The medical research company earned $4.16 million during the quarter, compared to analysts' expectations of $5.24 million. HTG Molecular Diagnostics had a negative net margin of 105.56% and a negative return on equity of 338.96%. View HTG Molecular Diagnostics' Earnings History.

3 brokers have issued 1-year target prices for HTG Molecular Diagnostics' stock. Their predictions range from $7.00 to $7.00. On average, they expect HTG Molecular Diagnostics' stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 120.8% from the stock's current price. View Analyst Ratings for HTG Molecular Diagnostics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to HTG Molecular Diagnostics include Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), Eyepoint Pharmaceuticals (EYPT), Arrayit Corp common stock (ARYC), Aethlon Medical (AEMD), Precipio (PRPO), Pressure Biosciences (PBIO), Scientific Industries (SCND) and PositiveID (PSID).

(HTGM) raised $50 million in an IPO on Wednesday, May 6th 2015. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. Leerink Partners served as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Media coverage about HTGM stock has been trending somewhat positive on Monday, Accern reports. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. HTG Molecular Diagnostics earned a coverage optimism score of 0.07 on Accern's scale. They also assigned news coverage about the medical research company an impact score of 44.78 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Shares of HTGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HTGM stock can currently be purchased for approximately $3.17.

HTG Molecular Diagnostics has a market capitalization of $90.35 million and generates $14.76 million in revenue each year. The medical research company earns $-18,960,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. HTG Molecular Diagnostics employs 98 workers across the globe.

HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at 877-289-2615.